Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could SignalThe Motley Fool • 09/21/26
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 09/17/26
Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking Alpha • 09/17/26
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees24/7 Wall Street • 09/16/26
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 09/15/26
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026PRNewsWire • 09/15/26
Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar CompetitionMarketBeat • 09/14/26
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your PortfolioZacks Investment Research • 09/14/26
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerPRNewsWire • 09/14/26
The Closest Thing to Set-It-and-Forget-It Income: 5 Dividend Kings for Retirees Who Want Peace of Mind24/7 Wall Street • 09/12/26